Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMFA glycovectors
- Development stage
- Preclinical
- Lead developer
- CellmAbs
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Drug Delivery Systems, Small Molecules
01
Overview
AMFA glycovectors are mannose 6-phosphonate derivatives (M6Pn) designed as unique glycovector molecules to enhance the cellular internalization of proteins and therapeutic agents. These synthetic glycoconjugates mimic natural mannose-6-phosphate but with increased stability and affinity for the cation-independent mannose-6-phosphate receptor (CI-MPR), facilitating targeted delivery into cells. They have been investigated as drug delivery enhancers, particularly in the context of enzyme replacement therapies such as for Pompe disease, where they improve uptake of therapeutic enzymes by target tissues[1][3]. The technology is being developed to optimize antibody-based immunotherapies and other biologics by improving their pharmacokinetics and tissue targeting.
- Other names
- AMFAMannose 6-phosphonate derivativesMannose6-phosphonate derivativesMannose-6-phosphonate derivativesM6Pn glycovectorsM-6Pn glycovectorsM 6Pn glycovectors
02
Targets
IGF2R (Cation-independent mannose-6-phosphate receptor)
Beyond the preview
Go deeper on AMFA glycovectors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMFA glycovectors.